Helen Minnaar

Helen Minnaar

Auto-generated profile, based on publicly available information

Helen Minnaar

St. Luke's Cancer Centre, Royal Surrey Hospital, Guildford, Surrey, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
JSJacqueline Steinke
Jacqueline Steinke
CJChloe Jordan
Chloe Jordan
SRSavvas Rossides
Savvas Rossides
HMHelen Minnaar
Helen Minnaar
JYJimmy Yu
Jimmy Yu
ASAlexandra J. Stewart
Alexandra J. Stewart
The use of external beam radiotherapy (EBRT) and contact X-Ray brachytherapy (CXB) is emerging as an effective alternative in patients with early stage rectal cancer with the intent of organ preservation (OP). Short course radiotherapy (SCRT) is an alternative EBRT schedule for patients not fit for chemotherapy or for longer courses of EBRT. There are no multicentre studies that have reported on the outcomes of SCRT with a CXB boost, therefore we present these from patients from centres from the UK and Sweden. From the Guildford Colorectal Database or local databases, 258 patients who underwent SCRT and CXB with the intent of OP from five centres treated between 2007 and 2019 were identified. Response and survival data was analysed and presented. With a median age of 81, 226 patients were treated with radiotherapy alone (RTA) and 32 immediately after local excision (ILE). Median follow-up was 24 months. 70% and 97% of patients in the RTA and ILE groups respectively had a complete clinical response (cCR) after SCRT with CXB. Of those, local relapse was seen in 16% of the RTA and 3% of the ILE group. Median survival was 40 months after CXB in the RTA and 52 months in the ILE group. 94% of patients remained stoma-free to the point of latest follow-up. This data suggests that CXB when combined with SCRT, in a mainly elderly and comorbid population, provides good palliation with stoma-avoidance. Oncological outcomes compare with previously published work. A greater focus is required on quality of life outcomes after OP.

6 September 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
NTNgu Wah Than
Ngu Wah Than
DPD. Mark Pritchard
D. Mark Pritchard
DHDavid M. Hughes
David M. Hughes
KYKai Shing Yu
Kai Shing Yu
HMHelen S. Minnaar
Helen S. Minnaar
AMArthur Sun Myint
Arthur Sun Myint
Radical surgery is the standard of care for early rectal cancer. However, alternative organ-preserving approaches are attractive, especially in frail or elderly patients as these avoid surgical complications. We have assessed the efficacy of sole Contact X-ray Brachytherapy (CXB) treatment in stage-1 rectal cancer patients who were unsuitable for or declined surgery. This retrospective multi-centre study (2009–2021) evaluated 76 patients with T1/2-N0-M0 rectal adenocarcinomas who were treated with CXB alone. Outcomes were assessed for the entire cohort and sub-groups based on the T-stage and the criteria for receiving CXB alone; Group A: patients who were fit enough for surgery but declined, Group B: patients who were high-risk for surgery and Group C: patients who had received prior pelvic radiation for a different cancer. With a median follow-up of 26(IQR:12–49) months, initial clinical Complete Response (cCR) was 82(70–93)% with rates of local regrowth 18(8–29)%, 3-year actuarial local control (LC) 84(75–95)%, distant relapse 3 %, and no nodal relapse. 5-year disease-free survival (DFS) and overall survival (OS) were 66(48–78)% and 58(44–75)%. Lower OS was observed in Groups B [HR:2.54(95 %CI:1.17, 5.59), p = 0.02] and C [HR:2.75(95 %CI:1.15, 6.58), p = 0.03]. Previous pelvic radiation predicted lower cCR and OS. The main toxicity was G1-2 rectal bleeding (26 %) and symptoms of impaired anal sphincter function were not reported in any patients. CXB treatment alone achieved a high cCR rate with satisfactory LC and DFS. Inferior oncological outcomes were observed in patients who had received prior pelvic radiotherapy. CXB alone, with its favourable toxicity profile and avoidance of general anaesthesia and surgery risks, therefore, can be considered for patients who are unsuitable for or refuse surgery.

4 November 2022 in Clinical Oncology
Verified
Journal Article
Closed access
JSJacqueline Steinke
Jacqueline Steinke
AFAdrian Franklin
Adrian Franklin
HMHelen Minnaar
Helen Minnaar
NPNina Patel
Nina Patel
CJChloe Jordan
Chloe Jordan
ASAlexandra Stewart
Alexandra Stewart

4 November 2022 in Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JSJacqueline Steinke
Jacqueline Steinke
AFAdrian Franklin
Adrian Franklin
CJChloe Jordan
Chloe Jordan
SRSavvas Rossides
Savvas Rossides
HMHelen Minnaar
Helen Minnaar
ASAlexandra Stewart
Alexandra Stewart